Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

August 5, 2025 updated by: Isaac Melamed, MD, IMMUNOe Research Centers

A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection

Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study will last approximately 19 weeks including 16 infusions total, each one week apart. This is to help patients that have developed "Post-Viral Fatigue Syndrome" which can include symptoms such as: extreme fatigue, lost of taste, brain fog, and/or seizures.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Colorado
      • Centennial, Colorado, United States, 80112
        • IMMUNOe Research Centers

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age 18 and older, male or female
  2. Previous confirmed diagnosis of SARS-CoV-2
  3. Experiencing SARS-CoV-2 post-viral fatigue syndrome 4 weeks after recovery for SARS-CoV-2
  4. Experiencing neurological symptoms including fatigue
  5. Willing to comply with all aspects of the protocol, including blood draws
  6. Patient is able to understand and fully participate in the activities of the study and the consent in accordance with guidelines
  7. Female patients of childbearing potential who are sexually active must be willing to use an acceptable form of contraception. Acceptable forms of contraception are defined as those with a failure rate of < 1% when properly applied and include: a combination pill, some intra-uterine devices, and a sterilized partner in a stable relationship. Female patients must not be pregnant, planning to become pregnant, or be actively breastfeeding through the entire period.

Exclusion Criteria:

  1. Receiving any form of C1-INH therapy either acute or prophylactic treatment
  2. History or suspicion of allergy to rabbits
  3. Neurological conditions related to injury
  4. Neuropathy related to diabetes
  5. Participants who are pregnant or lactating
  6. Largely incapacitated or bed ridden
  7. Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued with 30 days of study entry from any other clinical study involving an investigational product
  8. Patients who, in the investigator's opinion, might not be suitable for the trial for safety reasons

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Drug: Ruconest
C1 Esterase Inhibitor
Active Comparator: RUCONEST
IV Ruconest
Drug: Ruconest
C1 Esterase Inhibitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neuropsychological Measures (BRIEF-A)
Time Frame: Week 0
Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)
Week 0
Neuropsychological Measures (BRIEF-A)
Time Frame: Week 9
Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)
Week 9
Neuropsychological Measures (BRIEF-A)
Time Frame: Week 17
Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)
Week 17
Neuropsychological Measures (RBANS)
Time Frame: Week 0
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Week 0
Neuropsychological Measures (RBANS)
Time Frame: Week 9
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Week 9
Neuropsychological Measures (RBANS)
Time Frame: Week 17
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Week 17
Neuropsychological Measures (BDI II)
Time Frame: Week 0
Beck Depression Inventory II (BDI II)
Week 0
Neuropsychological Measures (BDI II)
Time Frame: Week 9
Beck Depression Inventory II (BDI II)
Week 9
Neuropsychological Measures (BDI II)
Time Frame: Week 17
Beck Depression Inventory II (BDI II)
Week 17
Neuropsychological Measures (MoCA)
Time Frame: Week 0
Montreal Cognitive Assessment (MoCA)
Week 0
Neuropsychological Measures (MoCA)
Time Frame: Week 9
Montreal Cognitive Assessment (MoCA)
Week 9
Neuropsychological Measures (MoCA)
Time Frame: Week 17
Montreal Cognitive Assessment (MoCA)
Week 17
Patient-Rate Questionnaires (FSS)
Time Frame: Week 0
Fatigue Severity Scale (FSS)
Week 0
Patient-Rate Questionnaires (FSS)
Time Frame: Week 5
Fatigue Severity Scale (FSS)
Week 5
Patient-Rate Questionnaires (FSS)
Time Frame: Week 9
Fatigue Severity Scale (FSS)
Week 9
Patient-Rate Questionnaires (FSS)
Time Frame: Week 14
Fatigue Severity Scale (FSS)
Week 14
Patient-Rate Questionnaires (FSS)
Time Frame: Week 17
Fatigue Severity Scale (FSS)
Week 17
Patient-Rate Questionnaires (MIDAS)
Time Frame: Week 0
Migraine Disability Assessment (MIDAS)
Week 0
Patient-Rate Questionnaires (MIDAS)
Time Frame: Week 5
Migraine Disability Assessment (MIDAS)
Week 5
Patient-Rate Questionnaires (MIDAS)
Time Frame: Week 9
Migraine Disability Assessment (MIDAS)
Week 9
Patient-Rate Questionnaires (MIDAS)
Time Frame: Week 14
Migraine Disability Assessment (MIDAS)
Week 14
Patient-Rate Questionnaires (MIDAS)
Time Frame: Week 17
Migraine Disability Assessment (MIDAS)
Week 17
Patient-Rate Questionnaires (HIT)
Time Frame: Week 0
Headache Impact Scale (HIT)
Week 0
Patient-Rate Questionnaires (HIT)
Time Frame: Week 5
Headache Impact Scale (HIT)
Week 5
Patient-Rate Questionnaires (HIT)
Time Frame: Week 9
Headache Impact Scale (HIT)
Week 9
Patient-Rate Questionnaires (HIT)
Time Frame: Week 14
Headache Impact Scale (HIT)
Week 14
Patient-Rate Questionnaires (HIT)
Time Frame: Week 17
Headache Impact Scale (HIT)
Week 17
Patient-Rate Questionnaires (Activities)
Time Frame: Week 0
Activities of Daily Living Sliding Scale and Questionnaire
Week 0
Patient-Rate Questionnaires (Activities)
Time Frame: Week 5
Activities of Daily Living Sliding Scale and Questionnaire
Week 5
Patient-Rate Questionnaires (Activities)
Time Frame: Week 9
Activities of Daily Living Sliding Scale and Questionnaire
Week 9
Patient-Rate Questionnaires (Activities)
Time Frame: Week 14
Activities of Daily Living Sliding Scale and Questionnaire
Week 14
Patient-Rate Questionnaires (Activities)
Time Frame: Week 17
Activities of Daily Living Sliding Scale and Questionnaire
Week 17
Patient-Rate Questionnaires (SF)
Time Frame: Week 0
SF McGill Pain Questionnaire
Week 0
Patient-Rate Questionnaires (SF)
Time Frame: Week 5
SF McGill Pain Questionnaire
Week 5
Patient-Rate Questionnaires (SF)
Time Frame: Week 9
SF McGill Pain Questionnaire
Week 9
Patient-Rate Questionnaires (SF)
Time Frame: Week 14
SF McGill Pain Questionnaire
Week 14
Patient-Rate Questionnaires (SF)
Time Frame: Week 17
SF McGill Pain Questionnaire
Week 17
Patient-Rate Questionnaires (GSRS)
Time Frame: Week 0
Gastrointestinal Symptoms Rating Scale (GSRS)
Week 0
Patient-Rate Questionnaires (GSRS)
Time Frame: Week 5
Gastrointestinal Symptoms Rating Scale (GSRS)
Week 5
Patient-Rate Questionnaires (GSRS)
Time Frame: Week 9
Gastrointestinal Symptoms Rating Scale (GSRS)
Week 9
Patient-Rate Questionnaires (GSRS)
Time Frame: Week 14
Gastrointestinal Symptoms Rating Scale (GSRS)
Week 14
Patient-Rate Questionnaires (GSRS)
Time Frame: Week 17
Gastrointestinal Symptoms Rating Scale (GSRS)
Week 17
Patient-Rate Questionnaires (SF-36)
Time Frame: Week 0
SF-36
Week 0
Patient-Rate Questionnaires (SF-36)
Time Frame: Week 5
SF-36
Week 5
Patient-Rate Questionnaires (SF-36)
Time Frame: Week 9
SF-36
Week 9
Patient-Rate Questionnaires (SF-36)
Time Frame: Week 14
SF-36
Week 14
Patient-Rate Questionnaires (SF-36)
Time Frame: Week 17
SF-36
Week 17
Neurological Exam (0)
Time Frame: Week 0
Complete neurological examination
Week 0
Neurological Exam (9)
Time Frame: Week 9
Complete neurological examination
Week 9
Neurological Exam (17)
Time Frame: Week 17
Complete neurological examination
Week 17
Immunological Biomarkers (Toll)
Time Frame: Week 1
Toll Like Receptor Function Assay
Week 1
Immunological Biomarkers (Toll)
Time Frame: Week 9
Toll Like Receptor Function Assay
Week 9
Immunological Biomarkers (Toll)
Time Frame: Week 17
Toll Like Receptor Function Assay
Week 17
Immunological Biomarkers (GAD)
Time Frame: Week 1
GAD-65
Week 1
Immunological Biomarkers (GAD)
Time Frame: Week 9
GAD-65
Week 9
Immunological Biomarkers (GAD)
Time Frame: Week 17
GAD-65
Week 17
Immunological Biomarkers (Com)
Time Frame: Week 1
Complement Panel (C4, C1-INH, C1-INH Function)
Week 1
Immunological Biomarkers (Com)
Time Frame: Week 9
Complement Panel (C4, C1-INH, C1-INH Function)
Week 9
Immunological Biomarkers (Com)
Time Frame: Week 17
Complement Panel (C4, C1-INH, C1-INH Function)
Week 17
Immunological Biomarkers (Ig)
Time Frame: Week 1
Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)
Week 1
Immunological Biomarkers (Ig)
Time Frame: Week 9
Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)
Week 9
Immunological Biomarkers (Ig)
Time Frame: Week 17
Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)
Week 17
Immunological Biomarkers (IgG)
Time Frame: Week 1
Immunoglobulins G, Subclasses (1-4)
Week 1
Immunological Biomarkers (IgG)
Time Frame: Week 9
Immunoglobulins G, Subclasses (1-4)
Week 9
Immunological Biomarkers (IgG)
Time Frame: Week 17
Immunoglobulins G, Subclasses (1-4)
Week 17
Immunological Biomarkers (TH/TH)
Time Frame: Week 1
TH1/TH2 Cytokine Levels
Week 1
Immunological Biomarkers (TH/TH)
Time Frame: Week 9
TH1/TH2 Cytokine Levels
Week 9
Immunological Biomarkers (TH/TH)
Time Frame: Week 17
TH1/TH2 Cytokine Levels
Week 17

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

IMMUNOe Research Centers

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 11, 2021

Primary Completion (Actual)

March 30, 2024

Study Completion (Actual)

July 1, 2024

Study Registration Dates

First Submitted

January 7, 2021

First Submitted That Met QC Criteria

January 8, 2021

First Posted (Actual)

January 12, 2021

Study Record Updates

Last Update Posted (Actual)

August 11, 2025

Last Update Submitted That Met QC Criteria

August 5, 2025

Last Verified

January 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IIS202001-Neuroimmune

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Ruconest

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe